SU014813

SU014813 is an orally-active, small molecule multitargeted tyrosine kinase inhibitor with potential antitumor activity. It binds to and inhibits the phosphorylation of several receptor tyrosine kinases including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptors (PDGFR) alpha and beta, c-Kit (KIT), and Fms-like tyrosine kinase 3 (FLT3). This inhibition leads to reduced cellular proliferation and angiogenesis as well as induction of apoptosis in tumor cells. Developed as a next-generation agent following sunitinib, it was designed for improved pharmacokinetic and tolerability profiles. Clinical studies have evaluated its use in combination with docetaxel for advanced solid tumors such as melanoma and gastrointestinal stromal tumors refractory to other TKIs[1][2][5][7].

Other names

1H-Pyrrole-3-carboxamide, 5-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-N-((2S)-2-hydroxy-3-(4-morpholinyl)propyl)-2,4-dimethyl-